PCSA
NASDAQ · Pharmaceuticals
Processa Pharmaceuticals Inc
$2.41
+0.08 (+3.43%)
Financial Highlights (FY 2025)
Revenue
2.71M
Net Income
319.8K
Gross Margin
66.1%
Profit Margin
11.8%
Rev Growth
+2.4%
D/E Ratio
0.28
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 66.1% | 66.1% | 66.1% |
| Operating Margin | 16.9% | 15.3% | 16.7% |
| Profit Margin | 11.8% | 12.3% | 15.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.71M | 2.46M | 2.10M |
| Gross Profit | 1.79M | 1.62M | 1.39M |
| Operating Income | 456.4K | 375.7K | 351.0K |
| Net Income | 319.8K | 302.9K | 327.4K |
| Gross Margin | 66.1% | 66.1% | 66.1% |
| Operating Margin | 16.9% | 15.3% | 16.7% |
| Profit Margin | 11.8% | 12.3% | 15.6% |
| Rev Growth | +2.4% | +0.4% | +18.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.15M | 1.26M | 1.21M |
| Total Equity | 4.18M | 3.59M | 4.27M |
| D/E Ratio | 0.28 | 0.35 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 521.3K | 563.7K | 431.6K |
| Free Cash Flow | 364.0K | 435.1K | 285.7K |